"Annexin A5" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A protein of the annexin family isolated from human PLACENTA and other tissues. It inhibits cytosolic PHOSPHOLIPASE A2, and displays anticoagulant activity.
| Descriptor ID |
D017304
|
| MeSH Number(s) |
D12.776.157.125.050.100
|
| Concept/Terms |
Annexin A5- Annexin A5
- Annexin V
- Placental Anticoagulant Protein I
- Endonexin II
- Lipocortin V
- Lipocortin-V
- Anchorin CII
- Calphobindin I
|
Below are MeSH descriptors whose meaning is more general than "Annexin A5".
Below are MeSH descriptors whose meaning is more specific than "Annexin A5".
This graph shows the total number of publications written about "Annexin A5" by people in this website by year, and whether "Annexin A5" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 1 | 2 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 2 | 1 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Annexin A5" by people in Profiles.
-
Annexin A5 as a targeting agent for cancer treatment. Cancer Lett. 2022 10 28; 547:215857.
-
Anionic phospholipid expression as a molecular target in Listeria monocytogenes and Escherichia coli. Int J Antimicrob Agents. 2020 Dec; 56(6):106183.
-
Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018 07 01; 425:174-182.
-
Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide. Mol Cancer Ther. 2017 09; 16(9):1855-1865.
-
Annexin-directed ß-glucuronidase for the targeted treatment of solid tumors. Protein Eng Des Sel. 2017 Feb; 30(2):85-94.
-
Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer. Pancreas. 2015 Aug; 44(6):945-52.
-
Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapy. PLoS One. 2013; 8(10):e76403.
-
Antitumor activity of an enzyme prodrug therapy targeted to the breast tumor vasculature. Cancer Invest. 2013 Oct; 31(8):505-10.
-
Targeting single-walled carbon nanotubes for the treatment of breast cancer using photothermal therapy. Nanotechnology. 2013 Sep 20; 24(37):375104.
-
Annexin V-targeted enzyme prodrug therapy using cytosine deaminase in combination with 5-fluorocytosine. Cancer Lett. 2011 Aug 01; 307(1):53-61.